BioSpace News Archive

MedinCell’s (Paris:MEDCL) partner, Teva, today announced that it recently completed the re-submission to a New Drug Application to the U.S. FDA for mdc-IRM, a risperidone subcutaneous Long-Acting Injectable (LAI) for the maintenance treatment of schizophrenia using MedinCell’s proprietary technology.

Nordic Nanovector ASA (OSE: NANOV) (“Nordic Nanovector” or the “Company”) announces the progress it has made in designing and developing a portfolio of novel and potent humanized anti-CD37 monoclonal antibodies with potential for treating B-cell malignancies or B-cell-driven autoimmune disorders.

NovalGen Ltd (“NovalGen”), a biopharmaceutical company developing breakthrough cancer therapies, alongside an auto-regulation platform, today announces the online publication of three abstracts submitted to the American Society of Hematology Annual meeting, to be held December 10-13, 2022.

Ardelyx, Inc. announced that new analyses of data from its three Phase 3 trials supporting the clinical utility of XPHOZAH will be presented at the American Society of Nephrology Kidney Week 2022, taking place in Orlando, Florida from November 3-6, 2022.

ValenzaBio, Inc., a biopharmaceutical company developing monoclonal antibody (mAb) therapeutics for autoimmune and inflammatory indications, today announced positive initial results from its open label Phase 1a/2b clinical trial of VB119, a B-cell depleting mAb with enhanced antibody-dependent cellular cytotoxicity and potent binding to CD19, for the treatment of primary membranous nephropathy (PMN).

Pacylex today announced that data from the ongoing Phase 1 dose escalation clinical trial of PCLX-001, an N-myristoyltransferase (NMT) inhibitor, as well as the scientific rationale for its use in acute myeloid leukemia (AML) patients, will be presented at the American Society of Hematology (ASH) Annual Meeting and Exposition from 10-13 December 2022.

BioPorto A/S announced that in connection with the release of its Interim Report for the third quarter of 2022, the Company’s management team will host an online investor presentation on November 9, 2022 at 14:00 Central European Time / 8:00 Eastern Time via HC Andersen Capital.

The Janssen Pharmaceutical Companies of Johnson & Johnson are committed to redefining treatment outcomes in the hematology setting and today announced that abstracts from more than 50 company-sponsored studies, plus more than 20 investigator-initiated studies, will be presented at the American Society of Hematology (ASH) Annual Meeting in New Orleans from December 10-13, 2022.

NGM Biopharmaceuticals, Inc. (NGM Bio) (Nasdaq: NGM) today announced the presentation of findings from post-hoc analyses of its randomized, double-masked, sham-controlled CATALINA Phase 2 trial of NGM621, a monoclonal antibody designed to inhibit activity of complement component 3 (C3), in patients with GA secondary to AMD at The Retina Society Annual Scientific Meeting taking place November 2 – 5, 2022 in Pasadena, Calif.

Novadip Biosciences announced that it has raised an additional EUR 40 million in a Series B equity round and non-dilutive funding.